Merck & Co (NY:MRK)

Merck Recommends Rejection of TRC Capital’s “Mini-Tender” Offer

November 22, 2024

Merck to Participate in the 7th Annual Evercore ISI HealthCONx Conference

November 22, 2024

Merck’s WELIREG® (belzutifan) Approved in China for the Treatment of Adult Patients With Certain Types of Von Hippel-Lindau (VHL) Disease-Associated Tumors

November 22, 2024

Surendralal Karsanbhai Elected to Merck Board of Directors

November 22, 2024

Pyxis Oncology announces mixed Phase 1 PYX-201 data, collaboration with Merck, and analyst downgrade citing limited efficacy beyond head-and-neck cancer.

Pyxis Oncology's Cancer Drug Progress Stirs Analyst Concerns ↗

November 21, 2024

Via Benzinga

2 Beaten-Down Healthcare Stocks to Buy Hand Over Fist ↗

November 21, 2024

Merck Data at the ASH 2024 Annual Meeting Highlights Promising Hematology Pipeline With Diverse Range of Investigational Assets and Novel Modalities

November 21, 2024

In a market where value is scarce, MERCK & CO. INC. (NYSE:MRK) offers a refreshing opportunity with its solid fundamentals.

NYSE:MRK appears to be flying under the radar despite its strong fundamentals. ↗

November 21, 2024

Via Chartmill

Merck's Multi-Billion Dollar Drug Keytruda's Investigational Under The Skin Injection At Par With Intravenous Formulation In Untreated Lung Cancer Patients ↗

November 19, 2024

Merck's Phase 3 trial shows subcutaneous pembrolizumab is as effective as IV Keytruda for first-line NSCLC treatment, meeting key pharmacokinetic goals.

Via Benzinga

Merck Announces First-Quarter 2025 Dividend

November 19, 2024

Merck Announces Phase 3 Trial of Subcutaneous Pembrolizumab With Berahyaluronidase Alfa Met Primary Endpoints

November 19, 2024

Thanks to the change in the Health and Human Services Department, 'big pharma' stocks are one of the very few sectors in equity-land that are seemingly unhappy about the forthcoming administration.

Not-So-Big Pharma ↗

November 16, 2024

Via Talk Markets

Powell Speaks The Truth - Market Does Not Like It, Consternation About Kennedy, Gaetz, And Hegseth ↗

November 15, 2024

To gain an edge, this is what you need to know today.

Via Benzinga

European And US Vaccine Stocks Are Under Pressure - Here's WHy ↗

November 15, 2024

Vaccine stocks react to Robert F. Kennedy Jr.'s HHS nomination. FDA and NIH express concerns over his anti-vaccine views amid market shifts.

Via Benzinga

Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment for Adult Patients With Unresectable Non-Epithelioid Malignant Pleural Mesothelioma (MPM)

November 15, 2024

Immutep's INSIGHT-003 Phase 1 trial reports promising survival data for 1L NSCLC treatment using eftilagimod alpha, Keytruda, and chemotherapy.

Immutep's Lead Cancer Drug Shows Promising 2-Year Survival Data In Lung Cancer Trial ↗

November 14, 2024

Via Benzinga

Merck Spends Up To $3.3 Billion In An Insurance Policy Against Summit Therapeutics ↗

November 14, 2024

Merck is spending up to $3.3 billion in a licensing deal for an anti-PD-1/VEGF drug from China.

Via Investor's Business Daily

Why Are These 3 Vanguard ETFs Underperforming the S&P 500 Since Election Day? ↗

November 14, 2024

Stocks in these "safe" sectors are selling off as investors gravitate toward growth.

Topics ETFs Stocks

Merck to Participate in the Jefferies London Healthcare Conference

November 14, 2024

Merck Enters into Exclusive Global License for LM-299, An Investigational Anti-PD-1/VEGF Bispecific Antibody from LaNova Medicines Ltd.

November 14, 2024

KOSELUGO® (selumetinib) Showed Significant and Clinically Meaningful Improvement in Objective Response Rate Versus Placebo in Adults With Neurofibromatosis Type 1 who Have Symptomatic, Inoperable Plexiform Neurofibromas in Global Phase 3 KOMET Trial

10 Health Care Stocks With Whale Alerts In Today's Session ↗

November 13, 2024

Via Benzinga

November 12, 2024

Merck to Present New Data From GARDASIL®9 Studies Reinforcing the Importance of Gender-Neutral HPV Vaccination in Adults Up to Age 45 at the International Papillomavirus Conference (IPVC) 2024

November 12, 2024

If you have been reading our posts you know that some of the big biotech winners have taken a hit after earnings : LLY, MRK and REGN. But ABBV, GILD, LLY, and VRTX remain among the top performers.

Biotech Stocks Are Rallying: What Is Your Playbook? ↗

November 11, 2024

Via Talk Markets

3 Stocks Poised for a Breakout ↗

November 09, 2024

All 3 stocks are high on my watchlist.

Markets rallied strongly this week on clarity about the election and an expected rate cut, but next week's inflation readings will determine if momentum lasts

MarketBeat Week in Review – 11/4 - 11/8

November 09, 2024

Via MarketBeat

Topics Economy Government

Bristol-Myers Squibb Leads Biopharma Recovery With Almost 25% Growth In Market Cap, But Novo Nordisk And Lilly Suffer Market Setbacks ↗

November 08, 2024

The global biopharmaceutical market saw a 2% increase in market capitalization in Q3 2024, led by growth from Bristol-Myers Squibb, Gilead Sciences, and Sanofi, despite challenges for Novo Nordisk and...

Via Benzinga

2 Hot Biopharma Stocks to Buy and Hold for 5 Years ↗

November 08, 2024

If you're patient, these businesses have a lot of promising projects in the works.

These stocks have seen better days but investors shouldn't count them out in the long run.

Got $5,000? These 3 Growth Stocks Are Trading Near Their 52-Week Lows. ↗

November 07, 2024